On Tuesday, Shares of Barrick Gold Corporation (NYSE:ABX), lost -4.88% to $10.32, as gold prices near a four month low level on a stronger dollar, Reuters reports.
The precious metal prices were down ahead of the emergency euro zone summit on Greece as the country runs out of cash, according to Reuters.
GOLD has fallen to a near four-month low, while silver has sunk nearly seven per cent and platinum has dropped to a 2009 low, as the US dollar rallied ahead of an emergency eurozone summit on Greece with the country’s banks rapidly running out of cash.
Spot gold dropped to its lowest since March 18 at $US1,148.05 an ounce and was down 1.1 per cent at $US1,156.75 by 3.45pm EDT.
Barrick Gold Corporation produces and sells gold and copper. The company is also involved in exploration and mine development activities. It conducts mining, development and exploration, and other activities in various countries, counting the United States, Canada, Australia, Argentina, Chile, Peru, the Dominican Republic, Papua New Guinea, Tanzania, Zambia, and Saudi Arabia.
Shares of Ctrip.com International Ltd. (NASDAQ:CTRP), declined -0.60% to $71.10, during its last trading session.
Ctrip.com International, declared the completion of US$700 million in aggregate principal amount of convertible senior notes due 2020 and US$400 million in aggregate principal amount of convertible senior notes due 2025. The notes were offered to qualified institutional buyers following Rule 144A under the United States Securities Act of 1933, as amended, and certain non-U.S. persons in compliance with Regulation S under the Securities Act. The Company has granted the initial purchaser a 30-day option to purchase up to an additional US$105 million principal amount of the 2020 notes and an additional US$60 million principal amount of the 2025 notes solely to cover over-allotments, if any. The 2020 notes will be convertible into Ctrip’s American depositary shares (“ADSs”), each representing as of the date of this press release 0.25 of an ordinary share of Ctrip, at the option of the holders, based on an initial conversion rate of 9.1942 of the Company’s ADSs per $1,000 principal amount of notes (which is equivalent to an initial conversion price of about US$108.76 per ADS and represents an about 45.0% conversion premium over the closing trading price of the Company’s ADSs on June 18, 2015, which was US$75.01 per ADS). The 2025 notes will be convertible into Ctrip’s ADSs, at the option of the holders, based on an initial conversion rate of 9.3555 of the Company’s ADSs per $1,000 principal amount of notes (which is equivalent to an initial conversion price of about US$106.89 per ADS and represents an about 42.5% conversion premium over the closing trading price of the Company’s ADSs on June 18, 2015 of US$75.01 per ADS). The conversion rate for each of the 2020 notes and the 2025 notes is subject to adjustment upon the occurrence of certain events.
The 2020 notes will bear interest at a rate of 1.0% per year, payable semiannually in arrears on January 1 and July 1 of each year, starting on January 1, 2016. The 2020 notes will mature on July 1, 2020, unless formerly repurchased or converted in accordance with their terms preceding to such date. The 2025 notes will bear interest at a rate of 1.99% per year, payable semiannually in arrears on January 1 and July 1 of each year, starting on January 1, 2016. The 2025 notes will mature on July 1, 2025, unless formerly repurchased or converted in accordance with their terms preceding to such date.
Ctrip.com International, Ltd., together with its auxiliaries, provides travel services for hotel accommodations, transportation ticketing services, packaged tours, and corporate travel administration in the People’s Republic of China. It also offers independent leisure travelers bundled packaged-tour products, counting group tours, semi-group tours, and private tours or packaged tours with various transportation arrangements, such as cruise, bus, or self-driving.
Finally, Sequenom Inc. (NASDAQ:SQNM), ended its last trade with -1.68% loss, and closed at $2.93.
On June 18, Sequenom, declared that its shareholders elected Catherine J. Mackey, Ph.D., as a new member of its Board of Directors, effective June 17, 2015. Dr. Mackey has also been designated to the Audit and Nominating and Corporate Governance committees of the Company’s Board of Directors.
“We are happy to welcome Dr. Mackey to our board, and we look forward to drawing on her more than 30 years of executive leadership and strong expertise in research and development as we expand our testing portfolio and drive continued growth for the company,” said Kenneth F. Buechler, Ph.D., Chairman of Sequenom, Inc.’s Board of Directors.
Sequenom, Inc., a life sciences company, develops and commercializes molecular diagnostics testing services for the women’s health and oncology markets in the United States and internationally. The company provides molecular based laboratory developed tests (LDTs) comprising MaterniT21 PLUS LDT, a noninvasive prenatal test (NIPT) to detect fetal chromosomal abnormalities.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
